Morten Karsdal, CEO of Nordic Bioscience, reflects on the PRO-C3 biomarker in tumor fibrosis FDA Letter of Support
"I want to be part of helping patients" said Morten Karsdal, CEO of Nordic Bioscience.
Nordic Bioscience has a successful track record of developing and marketing biomarkers for research in a broad range of chronic diseases with a fibrotic component. In recent years, the concept of tumor fibrosis, which encompasses the tumor microenvironment, cancer-associated fibroblasts, and the extracellular matrix, has gained significant attention.
The FDA’s LoS demonstrates that Nordic Bioscience’s PRO-C3 biomarker is uniquely positioned to support research and clinical trials in this area.
